| Literature DB >> 26577806 |
Sara R Martins-Neves1, Daniela I Paiva-Oliveira2, Pauline M Wijers-Koster3, Antero J Abrunhosa4, Carlos Fontes-Ribeiro5, Judith V M G Bovée3, Anne-Marie Cleton-Jansen3, Célia M F Gomes6.
Abstract
Development of resistance represents a major drawback in osteosarcoma treatment, despite improvements in overall survival. Treatment failure and tumor progression have been attributed to pre-existing drug-resistant clones commonly assigned to a cancer stem-like phenotype. Evidence suggests that non stem-like cells, when submitted to certain microenvironmental stimuli, can acquire a stemness phenotype thereby strengthening their capacity to handle with stressful conditions. Here, using osteosarcoma cell lines and a mouse xenograft model, we show that exposure to conventional chemotherapeutics induces a phenotypic cell transition toward a stem-like phenotype. This associates with activation of Wnt/β-catenin signaling, up-regulation of pluripotency factors and detoxification systems (ABC transporters and Aldefluor activity) that ultimately leads to chemotherapy failure. Wnt/β-catenin inhibition combined with doxorubicin, in the MNNG-HOS cells, prevented the up-regulation of factors linked to transition into a stem-like state and can be envisaged as a way to overcome adaptive resistance. Finally, the analysis of the public R2 database, containing microarray data information from diverse osteosarcoma tissues, revealed a correlation between expression of stemness markers and a worse response to chemotherapy, which provides evidence for drug-induced phenotypic stem cell state transitions in osteosarcoma.Entities:
Keywords: Aldehyde dehydrogenase; Osteosarcoma; Pluripotency; Stemness; Wnt/β-catenin
Mesh:
Substances:
Year: 2015 PMID: 26577806 DOI: 10.1016/j.canlet.2015.11.013
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679